GlassScriptPhysician profile
Amanda Lynn Balk
NPI 1851806467
$2,700.12
in general payments reported to CMS, 2019-2025
35 companies · $1,372 in 2025
The $1,372 reported for 2025 was more than what 88% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $120 · 2023: $508 · 2024: $700 · 2025: $1,372.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,581.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,580.51 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $363.49 | 2023-2025 | |
| Astrazeneca Pharmaceuticals LP | $282.99 | 2022-2025 | Airsupra, Breztri, Farxiga |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $237.90 | 2022-2025 | Xifaxan |
| Lilly USA, LLC | $152.46 | 2022-2025 | Mounjaro, Trulicity |
| Otsuka America Pharmaceutical, INC. | $146.17 | 2023-2025 | Rexulti, Nuedexta |
| Alkermes, INC. | $139.92 | 2023-2025 | Aristada, Lybalvi |
| Axsome Therapeutics, INC. | $134.56 | 2023-2025 | Auvelity, Symbravo |
| Amgen INC. | $131.43 | 2023-2025 | Repatha, Otezla, Prolia |
| Neurocrine Biosciences, INC. | $105.62 | 2023-2025 | Ingrezza |
| Novo Nordisk INC | $94.82 | 2024-2025 | Ozempic, Rybelsus, Wegovy |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $80.01 | 2022-2025 | Caplyta |
| Philips North America LLC | $79.18 | 2022-2024 | (8874) Incourage |
| Bayer Healthcare Pharmaceuticals INC. | $73.98 | 2023-2025 | |
| Aimmune Therapeutics, INC. | $54.62 | 2024-2025 | Zenpep, Vowst |
| Janssen Pharmaceuticals, INC | $51.54 | 2023-2025 | Spravato |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Exact Sciences Corporation | $50.88 | 2025 | Cologuard Collection Kit |
| Merck Sharp & Dohme LLC | $50.16 | 2024-2025 | Verquvo |
| Azurity Pharmaceuticals, INC. | $50.09 | 2024-2025 | Edarbi, Azmiro, Horizant |
| Boehringer Ingelheim Pharmaceuticals, INC. | $48.10 | 2024-2025 | Jardiance |
| Takeda Pharmaceuticals U.S.A., INC. | $39.50 | 2024-2025 | Trintellix |
| Nevro Corp. | $37.43 | 2024 | Senza |
| Harmony Biosciences LLC | $32.89 | 2024 | |
| Viatris Specialty LLC | $32.56 | 2025 | Yupelri |
| Boston Scientific Corporation | $26.52 | 2025 | Watchman Flx |
| Kowa Pharmaceuticals America, INC. | $23.98 | 2023 | Seglentis |
| Xeris Pharmaceuticals, INC. | $22.55 | 2025 | Gvoke Hypopen |
| Radius Health, INC. | $21.43 | 2025 | Tymlos |
| Glaxosmithkline, LLC. | $18.49 | 2024 | Trelegy Ellipta |
| Novartis Pharmaceuticals Corporation | $17.93 | 2025 | |
| Teva Pharmaceuticals USA, INC. | $17.71 | 2025 | Uzedy |
| Protega Pharmaceutials INC | $17.60 | 2025 | Roxybond |
| Ardelyx, INC. | $17.19 | 2025 | Ibsrela |
| Phathom Pharmaceuticals, INC. | $17.14 | 2024 | Voquezna |
| Verona Pharma, INC. | $15.08 | 2025 | Ohtuvayre |
| Tris Pharma INC | $14.20 | 2025 | Dyanavel Xr |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amanda Balk listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.